Humacyte, Inc.
HUMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $1 | $7 |
| % Growth | 150.2% | -41.8% | -92.8% | – |
| Cost of Goods Sold | $0 | $2 | $2 | $4 |
| Gross Profit | $0 | -$2 | -$1 | $4 |
| % Margin | 65.5% | -588.7% | -282.8% | 50% |
| R&D Expenses | $17 | $22 | $15 | $21 |
| G&A Expenses | $0 | $8 | $8 | $7 |
| SG&A Expenses | $8 | $8 | $8 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $4 |
| Other Operating Expenses | $0 | -$2 | -$2 | $0 |
| Operating Expenses | $25 | $28 | $22 | $32 |
| Operating Income | -$24 | -$30 | -$23 | -$28 |
| % Margin | -3,239% | -9,876.1% | -4,484.3% | -388.6% |
| Other Income/Exp. Net | $7 | -$8 | $62 | $7 |
| Pre-Tax Income | -$18 | -$38 | $39 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$38 | $39 | -$21 |
| % Margin | -2,325.4% | -12,511% | 7,570.4% | -289.7% |
| EPS | -0.11 | -0.24 | 0.28 | -0.16 |
| % Growth | 54.2% | -185.7% | 275% | – |
| EPS Diluted | -0.11 | -0.24 | 0.28 | -0.16 |
| Weighted Avg Shares Out | 158 | 155 | 131 | 118 |
| Weighted Avg Shares Out Dil | 158 | 155 | 132 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$13 | -$33 | $44 | -$17 |
| % Margin | -1,730.8% | -11,047.5% | 8,505% | -230% |